Highlights and Quick Summary
- Change in payables and accrued liability for the quarter ending June 29, 2021 was $-2.78 Million (a -226.6% decrease compared to previous quarter)
- Year-over-year quarterly Change in payables and accrued liability decreased by -48.63%
- Annual Change in payables and accrued liability for 2020 was $974 Thousand (a 21.45% increase from previous year)
- Annual Change in payables and accrued liability for 2019 was $802 Thousand (a -40.01% decrease from previous year)
- Annual Change in payables and accrued liability for 2018 was $1.34 Million (a -727.7% decrease from previous year)
- Twelve month Change in payables and accrued liability ending June 29, 2021 was $-3.91 Million (a -200.72% decrease compared to previous quarter)
- Twelve month trailing Change in payables and accrued liability increased by 340.16% year-over-year
Trailing Change in payables and accrued liability for the last four month:
| 29 Jun '21 | 30 Mar '21 | 30 Dec '20 | 29 Sep '20 |
|---|---|---|---|
| $-3.91 Million | $3.89 Million | $973 Thousand | $-889 Thousand |
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Change in payables and accrued liability of PHASEBIO PHARMA
Most recent Change in payables and accrued liabilityof PHAS including historical data for past 10 years.Interactive Chart of Change in payables and accrued liability of PHASEBIO PHARMA
PHASEBIO PHARMA Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $-2.78 | $2.2 | – | – | – |
| 2020 | $2.09 | $-5.42 | $5.01 | $-0.71 | $0.97 |
| 2019 | $0.23 | $0.91 | $0.07 | $-1.53 | $0.8 |
| 2018 | $0.74 | $1.03 | $0.41 | $-0.26 | $1.34 |
| 2017 | – | – | – | $0.2 | $-0.21 |
| 2016 | – | – | – | – | $-0.34 |
Business Profile of PHASEBIO PHARMA
Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.